Fluicell AB (OSTO:FLUI) Other Financing: kr0.00 Mil (TTM As of Mar. 2026)


OSTO:FLUI Fluicell AB OSTO:FLUI
55 GF Score
Price kr33.10
GF Value kr34.54
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Other Financing?

Fluicell AB OSTO:FLUI +7.12% 55 Other Financing is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:FLUI with a GF Score™ of 55/100 and a GF Value™ of kr34.54 (Fairly Valued). The stock has 4 warning signs investors should review.

Fluicell AB's Other Financing for the three months ended in Mar. 2026 was kr0.00 Mil.

Fluicell AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Fluicell AB Other Financing Historical Data

* Premium members only.

The historical data trend for Fluicell AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB Other Financing Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.90 -5.72 -0.34 -5.19 0.00

Fluicell AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:FLUI
55GF Score
Fluicell AB OSTO:FLUI
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr0.00 Mil mean?
Fluicell AB (OSTO:FLUI) has a Other Financing of kr0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Fluicell AB and its competitors.
Is Fluicell AB's Other Financing too high?
Fluicell AB's current Other Financing is kr0.00 Mil. Overall, Fluicell AB has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Other Financing compare to VRTX and REGN?
Fluicell AB's Other Financing of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Fluicell AB and its competitors. Fluicell AB's current Other Financing is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Fairly Valued. The stock's GF Value™ is kr34.54, compared to a current price of kr33.10 — trading 4.2% below its estimated fair value. The current Other Financing is kr0.00 Mil. Fluicell AB's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Other Financing is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued. The current stock price of kr33.10 is trading 4.2% below its estimated GF Value™ of kr34.54. GuruFocus considers Fluicell AB to be Fairly Valued.

Key valuation signals for OSTO:FLUI:

  • Other Financing: kr0.00 Mil
  • GF Value™: kr34.54 vs. price of kr33.10 (4.2% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fluicell AB Business Description

Other Exchanges 5J90:Germany
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
55GF Score

Get the complete analysis for OSTO:FLUI

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr33.10
Price
kr34.54
GF Value